A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients
Phase 4
40 Years
N/A
40 Years
N/A
Not Enrolling
Female
Breast Neoplasms
Female
Breast Neoplasms
Trial Information
A Non-Interventional Study Evaluating The Effects Of Aromatase Inhibitor Treatment After 2-3 Years Tamoxifen - As Adjuvant Endocrine Therapy - On Quality Of Life And Safety In Endocrine Responsive Early Stage Postmenopausal Breast Cancer Patients
Group of patients using the same aromatase inhibitor
Inclusion Criteria:
Patients with endocrine responsive early stage postmenopausal breast cancer. Patients who
received tamoxifen for 2-3 years as adjuvant endocrine therapy. Patients who were approved
to switch to aromatase inhibitor treatment during the patient recruitment period.
Patients who were informed about the study and accepted to participate.
Exclusion Criteria:
Patients having a psychological disorder which will prevent their understanding of
questionnaires used for evaluation of quality of life and / or patients who are
illiterate.
Type of Study:
Observational
Study Design:
Observational Model: Cohort, Time Perspective: Prospective
Outcome Measure:
To evaluate the quality of life of patients with early stage postmenopausal breast cancer using aromatase inhibitor following 2-3 years of tamoxifen treatment (switch)
Outcome Time Frame:
2 years
Safety Issue:
Yes
Principal Investigator
Pfizer CT.gov Call Center
Investigator Role:
Study Director
Investigator Affiliation:
Pfizer
Authority:
Turkey: Ministry of Health, Directory of Pharmacies and Pharmaceuticals
Study ID:
A5991087
NCT ID:
NCT00784888
Start Date:
June 2008
Completion Date:
December 2011
Related Keywords:
- Breast Neoplasms
- aromatase inhibitor
- quality of life
- safety
- postmenopausal breast cancer
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
